爱硒健康网丨广东爱硒健康管理有限公司官网

2022ASCO摘要出炉!8大癌种重点研究抢先看

*仅供医学专业人士阅读参考

肿瘤国际大会来了!

2022年美国临床肿瘤学会(ASCO)大会即将在6月3-7日召开。昨日,ASCO大会官网公布了日程,其中在口头发言部分,有众多研究入选,各大癌种喜迎一波新进展,且多项中国研究也被纳入其中。在此,小编筛选大会上针对实体瘤的重点研究进行整理,让读者抢先感受ASCO年会的盛况。

一、肺癌:SCLC两大关键研究,NSCLC靶向新药遍地开花

小细胞肺癌:两项一线治疗III期研究亮相

今年ASCO大会上,备受瞩目的小细胞肺癌(SCLC)两项免疫治疗III期研究将会公布结果,一项是程颖教授牵头的中国原研PD-1抑制剂斯鲁利单抗联合化疗的结果。该方案已经获得2022年CSCO SCLC指南的一线治疗推荐,最终生存数据即将揭晓。另一项则是双免疫联合化疗一线治疗的结果,PD-L1单抗联合TIGIT单抗能否打造生存新高度?迫切等待。


入选研究:PD-1单抗斯鲁利单抗联合化疗 vs 单独化疗一线治疗广泛期小细胞肺癌:一项国际、随机III期研究

Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.

第一作者吉林省肿瘤医院 程颖教授


入选研究:阿替利珠单抗+化疗±TIGIT抑制剂tiragolumab一线治疗广泛期小细胞肺癌的III期研究结果:SKYSCRAPER-02


SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).

第一作者:Charles M. Rudin PhD, MD

非小细胞肺癌:KRAS/MET/EGFR20ins喜迎新药,免疫联合方案的探索不绝

对于非小细胞肺癌(NSCLC),靶向治疗方面,值得关注的新药有MRTX849、Amivantamab、CLN-081等,作用靶点包括KRAS/MET/EGFR20ins。在免疫治疗方面,除了公布纳武利尤单抗在早期肺癌新辅助治疗的研究结果外,还有免疫联合化疗、联合新靶点药物(LAG-3抑制剂、卡博替尼)的研究,以及免疫治疗基于生物标志物(PD-L1表达、KRAS)精准化治疗的进一步探索结果也将会出炉。总体而言,免疫治疗逐渐走向联合治疗以及个体化治疗。


入选研究:KRAS抑制剂MRTX849治疗KRAS G12C突变晚期非小细胞肺癌的疗效和安全性分析:KRYSTAL-1研究

KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation.

第一作者:Alexander I. Spira FACP, MD, PhD


入选研究:Amivantamab治疗MET14外显子跳跃突变非小细胞肺癌的CHRYSALIS试验更新结果

Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.

第一作者:Matthew Krebs FRCP, PhD


入选研究:EGFR抑制剂CLN-081治疗EGFR20号外显子插入突变非小细胞肺癌的I/IIa期试验

Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20).

第一作者:Helena Alexandra Yu MD


入选研究:纳武利尤单抗+化疗 vs 化疗新辅助治疗可切除IIIA期非小细胞肺癌患者:NADIM II期试验的主要终点病理完全缓解(pCR)结果

Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial.

第一作者:Mariano Provencio-Pulla MD, PhD


入选研究:在新诊断的IIIB-IV期NSCLC患者中,心理痛苦与生活质量和免疫检查点抑制剂疗效的相关性

Correlation of psychological distress with quality of life and efficacy of immune checkpoint inhibitors in patients with newly diagnosed stage IIIB-IV NSCLC.

第一作者中南大学湘雅二医院 吴芳教授


入选研究:在比较2周期与3周期的新辅助信迪利单抗联合铂类双药化疗在可切除非小细胞肺癌(neoSCORE)患者中的结果:随机对照、单中心、II期试验

Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): A randomized, single center, two-arm phase II trial.

第一作者:浙江大学医学院附属第二医院 邱福铭教授

入选研究:可溶性LAG-3蛋白eftilagimod alpha联合帕博利珠单抗一线治疗转移性非小细胞肺癌的II期试验(TACTI-002):PD-L1未选择人群的最新结果

A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.

第一作者:Enriqueta Felip PhD, MD

入选研究:FDA汇总分析:根据PD-L1表达和KRAS突变情况,免疫检查点抑制剂±化疗治疗晚期非小细胞肺癌的疗效

Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis.

第一作者:Erica C. Nakajima MD


入选研究:FDA汇总分析:PD-1/PD-L1单抗联合或不联合化疗一线治疗PD-L1表达≥50%晚期非小细胞肺癌

Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis.

第一作者:Oladimeji Akinboro MD, MPH


入选研究:卡博替尼+阿替利珠单抗vs卡博替尼单药治疗既往接受过免疫检查点抑制剂(ICI)的晚期非小细胞肺癌患者:COSMIC-021研究分析

Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.

第一作者:Joel W. Neal PhD, MD

二、乳腺癌:ADC大爆发,多靶点开花

在乳腺癌领域,今年ASCO口头报道的更新可说是眼花缭乱。首先,几款抗体偶联药物(ADC)强势发力,比如“明星药”DS-8201再次公布DB03研究的安全性结果,更值得关注的是,还有其在HER2低表达的III期临床研究结果。此外,针对TROP2的ADC药物sacituzumab govitecan(SG)在三阴性乳腺癌基础上继续迈进,将公布在HR+/HER2-人群中的数据。另外,还有HER3抑制剂在乳腺癌的初步研究结果将出炉。在HR+人群中,几款CDK4/6抑制剂将进一步更新研究结果,同样值得期待。


入选研究:DS-8201(T-DXd)对比恩美曲妥珠单抗治疗HER2阳性晚期乳腺癌患者:DESTINY-Breast03 III期研究的安全性分析

Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.

第一作者:Erika P. Hamilton MD

入选研究:DESTINY-Breast04 随机化III期研究:DS-8201对比医师选择治疗方案(TPC)用于HER2低表达晚期乳腺癌

Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.

第一作者:Shanu Modi MD

入选研究:TROP2的ADC药物sacituzumab govitecan对比医师选择治疗方案用于HR+/HER2-晚期乳腺癌患者:TROPiCS-02研究初期结果

Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer.

第一作者:Hope S. Rugo FASCO, MD

入选研究:哌柏西利+来曲唑 vs 安慰剂+来曲唑一线治疗ER+/HER2-晚期乳腺癌的生存结果:PALOMA-2研究分析

Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.

第一作者:Richard S. Finn MD


入选研究:靶向HER3的抗体偶联药物(ADC)U3-1402治疗HER3过表达转移性乳腺癌患者的I/II期研究结果

Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).

第一作者:Ian E. Krop PhD, MD

入选研究:地舒单抗辅助治疗在3425例乳腺癌患者的长期随访结果:ABCSG-18试验的骨折发生减少和生存数据

Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial.

第一作者:Michael Gnant FACS, MD

入选研究:KEYNOTE-522研究探索性分析:帕博利珠单抗+化疗对比安慰剂+化疗新辅助治疗三阴性乳腺癌根据残余肿瘤负担分析的无事件生存期(EFS)结果

Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.

第一作者:Lajos Pusztai D.Phil, MD

入选研究:AKT抑制剂capivasertib联合氟维司群vs安慰剂联合氟维司群治疗芳香化酶抑制剂进展的ER+晚期乳腺癌(FAKTION):总生存期(OS)和基于生物标志物分析的无进展生存期(PFS)结果

Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor–positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis.

第一作者:Robert Hugh Jones PhD

三、消化道肿瘤:两大中国研究亮相,联合治疗探索不停


在消化道肿瘤领域,由秦叔逵教授牵头的尼妥珠单抗联合化疗治疗胰腺癌的III期研究将会公布结果,期待该组合在“癌中之王”中的数据。另外,一项关于结直肠癌围手术期治疗的中国研究同样值得期待。


入选研究:尼妥珠单抗联合吉西他滨 vs吉西他滨治疗KRAS阴性晚期胰腺癌:一项前瞻性、随机对照、双盲、多中心III期临床试验

Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.

第一作者:南京金陵医院 秦叔逵教授


入选研究:mFOLFOX6或CAPOX用于局部晚期结肠癌患者的围手术期治疗(OPTICAL):一项多中心、随机、III期试验

Perioperative chemotherapy with mFOLFOX6 or CAPOX for patients with locally advanced colon cancer (OPTICAL): A multicenter, randomized, phase 3 trial.

第一作者:中山大学附属第六医院 胡华斌医师


入选研究:PARADIGM III期临床试验结果:帕尼单抗+mFOLFOX6对比贝伐珠单抗+mFOLFOX6一线治疗RAS野生型转移性结直肠癌

Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.

第一作者:Takayuki Yoshino PhD, MD

入选研究:帕尼单抗随机性间歇给药或持续性给药联合FOLFIRI一线治疗RAS/BRAF阴性晚期结直肠癌:IMPROVE试验

Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study.

第一作者:Antonio Avallone MD


入选研究:DS-8201治疗HER2过表达不可切除/复发性胆管癌患者:II期HERB研究


Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).

第一作者:Akihiro Ohba MD


四、头颈部肿瘤:多项中国创新研究登场,针灸治疗纳入口头报道


在头颈部肿瘤领域,马骏教授团队、麦海强教授团队、孙艳教授的研究均被纳入ASCO口头报道,可谓“中国之光”,鼻咽癌肿瘤的诊治贡献力量。

入选研究:单纯放疗对比同步放化疗治疗中危鼻咽癌:多中心、开放标签、非劣效性、随机III期试验

Radiotherapy alone versus concurrent chemoradiotherapy in intermediate risk nasopharyngeal carcinoma: A multicentre, open-label, noninferiority, randomised phase III trial.

第一作者:中山大学肿瘤防治中心 马骏教授


入选研究:治疗前根据EBV DNA选择低风险III期鼻咽癌的患者使用降剂量放疗:一项单臂、II期试验

Reduced-dose radiotherapy for pretreatment EBV DNA selected low-risk stage III nasopharyngeal carcinoma: A single-arm, phase II trial.

第一作者:中山大学肿瘤防治中心 麦海强教授


入选研究:尼妥珠单抗联合放化疗 vs安慰剂联合放化疗治疗局部晚期鼻咽癌患者:一项前瞻性、随机对照、双盲、多中心III期临床试验

Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.

第一作者:北京大学肿瘤医院 孙艳教授


入选研究:在头颈部肿瘤患者,针灸治疗放疗导致口腔干燥的III期试验

A phase III, randomized, sham-controlled trial of acupuncture for treatment of radiation-induced xerostomia (RIX) in patients with head and neck cancer: Wake Forest NCI Community Oncology Research Program Research Base (WF NCORP RB) trial WF-97115.

第一作者:Lorenzo Cohen PhD

五、泌尿系统肿瘤:新药枚不胜数,未来可期

在前列腺癌、尿路上皮癌等泌尿系统肿瘤领域,众多新药和新组合如SHR3680、PD-L1单抗+MET抑制剂+CTLA-4抑制剂、ADC药物等将会亮相,势必迎来一波诊治新热潮。


入选研究:在高瘤负荷转移性激素敏感性前列腺癌(mHSPC)患者中,比较雄激素受体拮抗剂SHR3680与比卡鲁胺联合雄激素剥夺治疗(ADT)的III期试验

A phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy (ADT) in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).

第一作者:复旦大学附属肿瘤医院 叶定伟教授


入选研究:TRUCE-02:一项替雷利珠单抗联合白蛋白紫杉醇治疗高风险非肌层浸润性尿路上皮膀胱癌的开放标签、单臂、II期研究

TRUCE-02: An open label, single-arm, phase II study of tislelizumab combined with nab-paclitaxel for high-risk non-muscle-invasive urothelial bladder carcinoma.

第一作者:天津医科大学第二医院 王海涛教授


入选研究:度伐利尤单抗单药或联合赛沃替尼/tremelimumab(CTLA-4抑制剂)用于经治晚期肾透明细胞癌的II期CALYPSO试验结果

CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer.

第一作者:Thomas Powles MD, PhD, FCRP


入选研究:恩杂卢胺治疗mHSPC的生存结果分析,来自ENZAMET研究

Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).

第一作者:Ian D. Davis PhD, MBBS, FRACP, FAChPM


入选研究:靶向CDH6的ADC新药DS-6000a治疗晚期肾细胞癌和卵巢肿瘤的I期试验

Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC).

第一作者:Erika P. Hamilton MD


入选研究:卡博替尼+阿替利珠单抗治疗尿路上皮癌:COSMIC-021研究的队列3、4和5结果

Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC): Results from Cohorts 3, 4, 5 of the COSMIC-021 study.

第一作者:Sumanta K. Pal FASCO, MD

六、妇科肿瘤:多项免疫联合新方案入选,双抗药物来袭


在妇科肿瘤领域,中国原研免疫双抗类药物AK104在宫颈癌的数据值得期待,此外,一些PD-1单抗联合方案在妇科肿瘤的探索也将逐步公布结果,相信免疫联合方案在妇科肿瘤的应用有望成为发展趋势。


入选研究:免疫双抗药物AK104(PD-1/CTLA-4双特异性抗体)联合标准疗法一线治疗持续性、复发性或转移性宫颈癌的研究

A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC)

第一作者:湖南省肿瘤医院 王静教授


入选研究:CDK4/6抑制剂rucaparib vs 安慰剂维持治疗一线含铂化疗晚期卵巢癌的III期试验:ATHENA–MONO (GOG-3020/ENGOT-ov45)

ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer.

第一作者:Bradley J. Monk MD


入选研究:PESCO I期和扩展队列的结果:帕博利珠单抗+maveropepimut-S(癌症疫苗)联合低剂量环磷酰胺治疗晚期上皮性卵巢癌

Pembrolizumab, maveropepimut-S, and low-dose cyclophosphamide in advanced epithelial ovarian cancer: Results from phase 1 and expansion cohort of PESCO trial.

第一作者:Ana Veneziani MD


入选研究:帕博利珠单抗+化疗治疗难治性、复发性或转移性宫颈癌:KEYNOTE-826研究的亚组分析

Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826.

第一作者:Krishnansu Sujata Tewari MD, FACS, FACOG


入选研究:靶向TF(组织因子)的ADC药物Tisotumab vedotin联合帕博利珠单抗一线治疗晚期宫颈癌的ENGOT Cx8/GOG 3024/innovaTV 205研究中期分析

Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205.

第一作者:Domenica Lorusso


入选研究:贝伐珠单抗联合化疗一线治疗晚期卵巢透明细胞癌在改善生存结果的作用:多中心回顾性分析

Bevacizumab in first-line chemotherapy to improve the survival outcome for advanced ovarian clear cell carcinoma: A multicenter, retrospective analysis.

第一作者:Toshiyuki Seki MD


七、黑色素瘤:免疫治疗是基础,组合千变万化

在黑色素瘤领域,中国学者斯璐教授的三联组合——免疫联合TKI+化疗一线治疗黑色素瘤的研究结果即将公布。同时,其他多项免疫联合方案的研究也将揭晓最终结果。

入选研究:卡瑞利珠单抗联合阿帕替尼和替莫唑胺一线治疗晚期肢端黑色素瘤患者的II期临床试验


A phase II clinical trial of camrelizumab (CAM, an IgG4 antibody against PD-1) combined with apatinib (APA, a VEGFR-2 tyrosine kinase inhibitor) and temozolomide (TMZ) as the first-line treatment for patients (pts) with advanced acral melanoma (AM).

第一作者:北京大学肿瘤医院 斯璐教授


入选研究:LAG-3抑制剂relatlimab联合纳武利尤单抗 vs 纳武利尤单抗一线治疗晚期黑色素瘤:RELATIVITY-047亚组分析

Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047.

第一作者:Hussein A. Tawbi PhD, MD


入选研究:阿替利珠单抗+MEK抑制剂cobimetinib+BRAF抑制剂维莫非尼治疗BRAF V600阳性脑转移的黑色素瘤患者:Tricotel II期试验结果

Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study.

第一作者:Reinhard Dummer MD


入选研究:帕博利珠单抗单药、序贯或同步联合达拉非尼+曲美替尼新辅助治疗BRAF突变III期可手术切除黑色素瘤的NeoTrio试验

NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy.

第一作者:Georgina V. Long MD, FRACP, PhD


八、其他:新靶点研究“白热化”,多款中国创新药物值得期待

入选研究:FRα/TRPV6双靶向配体-偶联药物CBP-1008治疗晚期实体瘤的Ia/Ib期研究结果

A phase Ia/Ib study of CBP-1008, a bispecific ligand drug conjugate, in patients with advanced solid tumors.

第一作者:中国医学科学院肿瘤医院 吴令英教授


入选研究:评估NY-ESO-1特异性TCR T细胞(TAEST16001)在基因型HLA-A*02:01晚期软组织肉瘤患者中的安全性、药代动力学(PK)、药效学(PD)和疗效的I期临床试验。

Phase I clinical trial to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of NY-ESO-1–specific TCR T-cells (TAEST16001) in HLA-A*02:01 patients with advanced soft tissue sarcoma.

第一作者:中山大学肿瘤防治中心 张星教授


入选研究:在新诊断的胶质母细胞瘤中,肌注INO-5401(一种靶向hTERT、WT1和PSMA的DNA疫苗)+INO-9012(IL-12免疫调节剂)和电穿孔疗法(EP)联合PD-1单抗cemiplimab治疗的结果

Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma.

第一作者:David A. Reardon MD


入选研究:HER3单抗seribantumab 治疗NRG1融合阳性晚期实体瘤:CRESTONE研究

CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions.

第一作者:Daniel R. Carrizosa MD, MS


入选研究:IL-15超级激动剂N-803联合卡介苗治疗卡介苗无效的膀胱原位癌和非肌肉浸润性膀胱癌

Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC).

第一作者:Karim Chamie MD


入选研究:TIM-3抑制剂cobolimab单药或联合PD-1抑制剂纳武利尤单抗或dostarlimab (AMBER)

Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER).

第一作者:Gerald Steven Falchook MD


入选研究:PPARα(过氧化物酶体增殖物激活受体α)抑制剂TPST-1120单药以及联合纳武利尤单抗治疗晚期实体瘤的I期研究

A phase 1 study of TPST-1120 as a single agent and in combination with nivolumab in subjects with advanced solid tumors.

第一作者:Mark Yarchoan MD


入选研究:白介素2(IL-2)免疫调节剂单药以及联合帕博利珠单抗治疗晚期实体瘤的ARTISTRY-1研究


Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.

第一作者:Ulka N. Vaishampayan MD


入选研究:SUMOylation小分子抑制剂TAK-981联合帕博利珠单抗治疗晚期实体瘤的Ib期多中心研究


A phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumors.

第一作者:Sanjay Goel MD, MS


入选研究:仑伐替尼+艾立布林治疗晚期脂肪肉瘤(LPS)和平滑肌肉瘤(LMS)的Ib/II期研究(LEADER)疗效更新


A phase Ib/II study of the combination of lenvatinib (L) and eribulin (E) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER): Efficacy updates.

第一作者:Tom Wei-Wu Chen MD

加硒教授微信:623296388,送食疗电子书,任选一本

分享到:更多 ()

评论 抢沙发

  • 昵称 (必填)
  • 邮箱 (必填)
  • 网址